Asgard Therapeutics appoints immunology expert Shane Olwill as Chief Development Officer
Published on 08/07/2025 at 18:06 | prnewswire.co.uk
Pioneering cancer immunology company Asgard strengthens leadership team as it progresses its lead asset AT-108 towards clinical trials Shane brings over two decades of expertise in immunology-driven drug discovery with a specialized focus on novel modalitiesAT-108 is a first-in-class, off-the-shelf cell reprogramming therapy that leads to personalized and potent anti-cancer immune responsesView original content:https://www.prnewswire.co.uk/news-releases/asgard-therapeutics-appoints-immunology-expert-shane-olwill-as-chief-development-officer-302411069.html
en | boerse | 67959192 |
